Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.
Ascletis Pharma Inc. has announced the commencement of dosing in its U.S. Phase I clinical trial for ASC50, an oral small molecule IL-17 inhibitor aimed at treating psoriasis. This trial marks a significant step in Ascletis’ efforts to develop a potentially best-in-class treatment for psoriasis, with the study evaluating the drug’s safety, tolerability, and preliminary efficacy. The successful progression of this trial could enhance Ascletis’ position in the biopharmaceutical industry, potentially offering a new therapeutic option for psoriasis patients.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on developing innovative drugs for the treatment of various diseases. The company specializes in creating oral small molecule inhibitors, with a particular emphasis on autoimmune and inflammatory diseases such as psoriasis.
Average Trading Volume: 6,604,380
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.3B
Learn more about 1672 stock on TipRanks’ Stock Analysis page.